Heute, 03:33
Deqa Should You Invest in Canadian Energy Stocks Right Now
Did you know that you can generate $2,800 per year in tax-free passive income in a Tax-Free Savings Account TFSA It true! Technically, you can get much more than that in TFSA income. Invested for a 10% yield, the $88,000 in contribution room that Canadians aged 32 and older have amassed can produce $8,800 per year in passive income not that trying for that level of passive income is a good idea, mind you. A 10% yi stanley becher eld is extraordinarily high by today standard, which means that the stanley cup investments carrying such yields are very risky. Unless you are very experienced, you are probably better off not wading into the high-yield space. The good news is that $2,800 in tax-free passive income in a TFSA is achievable with highly diversified newbie-friendly investments. Heck, with the yields on Guaranteed Investment Certificates GICs these days, you can even invest a maxed-out $88,000 TFSA in stanley cupe a humble GIC and collect $4,400 in interest income a year from now. Iwyn A Generational Opportunity to Be Had With Toronto-Dominion Bank (TSX:TD) Stock
Valeant Pharmaceuticals Intl Inc. TSX:VRX NYSE:VRX is r stanley water bottle eporting its third-quarter earnings results on Monday. Should investors consider buying its shares today or wait until afte vaso stanley r the earnings report The businessValeant is a global specialty pharmaceutical company that develops and markets prescription and non-prescription pharmaceutical products. The business focuses on dermato stanley cups uk logy, eye health, and other niche therapeutic areas that target growth markets.Sales growth, earnings growth, and valuationFrom 2010 to 2014, Valeant s sales increased at a high rate of over 40% per year. In the same period, its earnings per share EPS also grew at a rate of over 40% per year. The question is whether or not that high growth can be sustained.YearSales GrowthEPS Growth20102011108.6%46%201244%51%201362.7%47.3%201443.2%45.7%In the past month, the shares have come down 30% from a high of $319 due to questioning of its high-priced drugs. However, Valeant is not the only drug company that was affec
Did you know that you can generate $2,800 per year in tax-free passive income in a Tax-Free Savings Account TFSA It true! Technically, you can get much more than that in TFSA income. Invested for a 10% yield, the $88,000 in contribution room that Canadians aged 32 and older have amassed can produce $8,800 per year in passive income not that trying for that level of passive income is a good idea, mind you. A 10% yi stanley becher eld is extraordinarily high by today standard, which means that the stanley cup investments carrying such yields are very risky. Unless you are very experienced, you are probably better off not wading into the high-yield space. The good news is that $2,800 in tax-free passive income in a TFSA is achievable with highly diversified newbie-friendly investments. Heck, with the yields on Guaranteed Investment Certificates GICs these days, you can even invest a maxed-out $88,000 TFSA in stanley cupe a humble GIC and collect $4,400 in interest income a year from now. Iwyn A Generational Opportunity to Be Had With Toronto-Dominion Bank (TSX:TD) Stock
Valeant Pharmaceuticals Intl Inc. TSX:VRX NYSE:VRX is r stanley water bottle eporting its third-quarter earnings results on Monday. Should investors consider buying its shares today or wait until afte vaso stanley r the earnings report The businessValeant is a global specialty pharmaceutical company that develops and markets prescription and non-prescription pharmaceutical products. The business focuses on dermato stanley cups uk logy, eye health, and other niche therapeutic areas that target growth markets.Sales growth, earnings growth, and valuationFrom 2010 to 2014, Valeant s sales increased at a high rate of over 40% per year. In the same period, its earnings per share EPS also grew at a rate of over 40% per year. The question is whether or not that high growth can be sustained.YearSales GrowthEPS Growth20102011108.6%46%201244%51%201362.7%47.3%201443.2%45.7%In the past month, the shares have come down 30% from a high of $319 due to questioning of its high-priced drugs. However, Valeant is not the only drug company that was affec